• English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
The Eurozones January Sentix investor confidence index will be released in ten minutes.On January 12th, Hengrui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the Breakthrough Therapy Product List by the Center for Drug Evaluation of the National Medical Products Administration. SHR-1826 is an antibody-drug conjugate targeting c-Met. It binds specifically to the target antigen on the surface of tumor cells, is internalized into the tumor cells, and then kills them. A search reveals that a similar product, ABBV-399, received accelerated approval from the US FDA in May 2025 for the treatment of adult patients with advanced/metastatic non-squamous non-small cell lung cancer who have previously received systemic therapy and have high c-Met protein expression. To date, the cumulative R&D investment in the SHR-1826 injectable project is approximately RMB 125.5 million.On January 12th, Sanfangxiang issued an announcement stating that, according to preliminary calculations by its finance department, the company expects a negative net profit attributable to shareholders of the listed company for 2025, resulting in an operating loss for the year. The company will strictly comply with the relevant regulations, including the "Shanghai Stock Exchange Listing Rules," and expedite its financial accounting work, disclosing its 2025 performance forecast as soon as possible. The final financial data will be subject to the companys officially released 2025 annual report.On January 12, Longxun Technology announced that it submitted an application to the Hong Kong Stock Exchange for an overseas public offering of H shares and listing on the Main Board of the Hong Kong Stock Exchange on December 22, 2025, and published the application materials for this offering on the Hong Kong Stock Exchange website on the same day. The company has submitted the filing application materials for this offering to the China Securities Regulatory Commission (CSRC) in accordance with relevant regulations, and the CSRC recently accepted them.On January 12, it was reported that U.S. Immigration and Customs Enforcement (ICE) officers shot and killed 37-year-old Ryan Goode during an immigration enforcement operation in Minneapolis on January 7, sparking days of protests across the United States. On January 11, protests entered their sixth day in Minneapolis, New York, Oakland, Atlanta, and other cities. Residents of Minneapolis stated that this forced immigration enforcement by the federal government was tantamount to "terrorism." Other protesters stated that the U.S. governments attacks on immigrants domestically and its imperialist aggression abroad should both be opposed.

Does the price of gold have a bottom, or is it just a brief easing of selling pressure

Alina Haynes

Jul 08, 2022 11:58

 截屏2022-07-08 上午11.24.58.png

 

But there was no significant upward movement, no greater high than the day before, and no unmistakable sign that the current selling pressure had subsided. Instead, it appears that market investors are waiting to see what the upcoming two important data on inflation and employment will reveal.

 

The U.S. Labor Department will release the nonfarm payroll jobs data for June tomorrow, which will be the first significant report. The most recent inflationary figures will be released the next week when the BEA releases the CPI (Consumer Price Index) for the previous month. The confidence that the Federal Reserve will increase interest rates again this month is being anticipated by market players.

 

The current discussion, however, centers on whether the Fed would maintain its strong approach by simply hiking rates by 50 basis points, as opposed to implementing another 75-basis point rate hike, as it did in June. The Federal Reserve will continue to batten down the hatches as they have since March, regardless of what the employment and inflation reports show.

 

There is no disagreement, according to the FedWatch tool from the CME. This is due to the FedWatch tool's forecast that there is a 93.9 percent likelihood that the Fed would maintain its strong approach to combating inflation by implementing back-to-back rate rises of 34 percent.

 

The dual goals of achieving maximum employment and keeping inflation within a target range of 2 percent are no longer the Federal Reserve's primary concerns. Recent Federal Reserve FOMC remarks and minutes amply demonstrate the central bank's laser-like concentration on containing inflation, with full awareness that the escalating rate rises will cause an economic slowdown and a decline in the labor force.

 

Analysts and market players have been worried about this approach because they believe it would cause economic instability and a recession. According to the most recent consensus, employment growth is still strong but shrinking. This data is expected to show that there were about 272,000 new jobs added last month and that the unemployment rate remained constant at 3.6 percent.

 

The BEA will present the most recent inflation figures on Wednesday, July 13. We may anticipate that inflationary pressures will continue to run high with a potential spike when compared to the preceding month, if the most recent inflationary figures from Europe are any indicator of what the CPI report will show next week.

 

According to the most current economic data, the US economy has gotten worse, and consumer confidence has plummeted. However, it is also obvious that the Federal Reserve will continue to hike rates this month and in September in order to pursue its goal of bringing inflation down from its present high levels and 40-year highs.

 

It is most definitely a reasonable assumption that the current selling pressure in gold has not subsided given the extremely high likelihood that the Federal Reserve will implement a second straight rate rise of 75 basis points at the end of this month.